The Indian Council of Medical Research organized India’s largest biomedical technology transfer event, titled Medical Innovations Patent Mitra: Innovators-to-Industry Connect, in New Delhi on May 25, 2026. Shri Prataprao Jadhav, Union Minister of State for Health and Family Welfare, inaugurated the platform to facilitate the commercialisation of indigenous public health technologies. This landmark initiative saw the transfer of 41 medical innovations, including vaccines and diagnostic kits, to industry partners to strengthen the country’s healthcare ecosystem.
What is Medical Innovations Patent Mitra?
The Medical Innovations Patent Mitra is a flagship initiative launched by the Indian Council of Medical Research (ICMR) on 8 March 2025. It was established to provide end-to-end support to biomedical innovators, from the initial stage of assessing patentability to the final stage of technology transfer. Supported by NITI Aayog and the Department of Pharmaceuticals, the platform aims to protect the intellectual property of Indian scientists and reduce the country’s dependence on imported medical technologies.
While a similar initiative called MedTech Mitra (launched in December 2023) focuses on providing regulatory and clinical trial support for medical devices, Patent Mitra specifically addresses the technical and legal hurdles of the patenting process. By offering a no-cost platform for patent filing and maintenance, it ensures that groundbreaking research by Indian scientists is legally protected and commercially viable.
Strengthening the Innovators-to-Industry (I2I) Connect
The “Innovators-to-Industry (I2I) Connect” event served as a structured bridge between laboratory research and commercial manufacturing. During the summit, a total of 41 public health technologies were transferred to industry partners. These innovations cover a wide range of public health needs, from rapid diagnostic kits to advanced recombinant vaccines.
| Technology Category | Specific Innovations |
|---|---|
| Vaccines | Typhoid, Paratyphoid, Salmonella, and Shigella vaccines |
| Diagnostics | Rapid kits for Mpox, Tuberculosis (TB), and Japanese Encephalitis |
| Biomaterials | Inactivated KFD and Chandipura virus materials |
| Therapeutics | New biomedical solutions and medical devices |
The event also featured the release of the Indian Biomedical Patent Landscape Report, which provides a comprehensive analysis of the current state of medical patents in India.
Developing Vaccines for KFD and Chandipura Virus
A significant highlight of the event was the transfer of inactivated Kyasanur Forest Disease (KFD) and Chandipura virus biomaterials. This move is strategically aimed at tackling neglected tropical diseases that pose a perennial threat to public health in India.
Kyasanur Forest Disease (KFD)
Commonly known as “Monkey Fever”, KFD is a tick-borne viral hemorrhagic fever first identified in 1957 in the Kyasanur Forest of Karnataka. The disease is endemic to the forested regions of the Western Ghats, including Karnataka, Kerala, Tamil Nadu, Goa, and Maharashtra. It is transmitted to humans through the bite of infected hard ticks (Haemaphysalis spinigera) or contact with infected monkeys.
Chandipura Virus
The Chandipura virus belongs to the Rhabdoviridae family and is a major cause of Acute Encephalitis Syndrome (AES) in children under the age of 15. First isolated in 1965 in Maharashtra, the virus is primarily transmitted by sandflies. It is known for its rapid progression, often leading to death within 24 to 48 hours of the onset of symptoms.
By transferring well-characterized biomaterials for these viruses, ICMR is enabling the industry to fast-track the development of indigenous vaccines, filling a critical gap in India’s preventive healthcare framework.
ICMR: The Nodal Agency for Biomedical Research
The Indian Council of Medical Research (ICMR) is the apex body in India for the formulation and promotion of biomedical research. Established in 1911 as the Indian Research Fund Association (IRFA), it was later renamed in 1949. Headquartered in New Delhi, ICMR operates under the Department of Health Research within the Ministry of Health and Family Welfare.
Under the leadership of Director General Dr. Rajiv Bahl, ICMR is currently steering India toward the “Viksit Bharat 2047” vision. The council’s shift toward structured technology transfer through initiatives like Patent Mitra marks a transition from purely academic research to a more impact-driven, public-private partnership model.
Key Takeaways
- The Medical Innovations Patent Mitra: I2I Connect event was held in New Delhi to facilitate the transfer of indigenous public health technologies.
- A total of 41 technologies, including vaccines for Typhoid and diagnostics for Japanese Encephalitis, were transferred to industry partners.
- ICMR transferred inactivated biomaterials for Kyasanur Forest Disease (KFD) and Chandipura virus to support vaccine development.
- The Patent Mitra initiative was launched on 8 March 2025 to provide end-to-end support for biomedical patenting and commercialization.
- ICMR was established in 1911 (as IRFA) and renamed in 1949, with its headquarters in New Delhi.
- Kyasanur Forest Disease is a tick-borne viral fever endemic to the Western Ghats, while Chandipura virus causes encephalitis in children and is spread by sandflies.
